NRF2 and cancer: the good, the bad and the importance of context
Open accessThe DOI matches its Crossref record; 119 of the 120 references it cites were found in a registry or an index.
Abstract
Many studies of chemopreventive drugs have suggested that their beneficial effects on suppression of carcinogenesis and many other chronic diseases are mediated through activation of the transcription factor NFE2-related factor 2 (NRF2). More recently, genetic analyses of human tumours have indicated that NRF2 may conversely be oncogenic and cause resistance to chemotherapy. It is therefore controversial whether the activation, or alternatively the inhibition, of NRF2 is a useful strategy for the prevention or treatment of cancer. This Opinion article aims to rationalize these conflicting perspectives by critiquing the context dependence of NRF2 functions and the experimental methods behind these conflicting data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NRF2 is mutationally activated in 10–30% of different solid tumors including liver, lung, stomach, colon and other cancers and mutations typically disrupt the interaction between NRF2 and its E3 ligase KEAP1 (Kelch Like ECH Associated Protein 1) directly or by impeding KEAP1 co-factors CUL3 (Cullin 3) and CAND1 (Cullin Associated and Neddylation Dissociated 1) [2,5,6,7,8].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NRF2 is mutationally activated in 10–30% of different solid tumors including liver, lung, stomach, colon and other cancers and mutations typically disrupt the interaction between NRF2 and its E3 ligase KEAP1 (Kelch Like ECH Associated Protein 1) directly or by impeding KEAP1 co-factors CUL3 (Cullin 3) and CAND1 (Cullin Associated and Neddylation Dissociated 1) [2,5,6,7,8].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“NRF2 is activated and overexpressed in cancer to promote cancer cell survival; the cellular antioxidant system is largely regulated by NRF2 and its associated genes.30”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [30]
In the citing paper
“Furthermore, increased ROS levels facilitate the activation of HIF1α and NRF2 transcription factors, thus promoting transcriptional programs that further contribute to tumorigenesis (Bertout et al., 2008; Sporn and Liby, 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Sporn and Liby, 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Niture, S. K., Jain, A. K., & Jaiswal, A. K. (2009) · Journal of Cell Science · doi:10.1242/jcs.058537 · Cited by 192
RetractedPhosphorylation and Dephosphorylation of Tyrosine 141 Regulate Stability and Degradation of INrf2
Jain, A. K., Mahajan, S., & Jaiswal, A. K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709854200 · Cited by 49
RetractedHsp90 Interaction with INrf2(Keap1) Mediates Stress-induced Nrf2 Activation
Niture, S. K., & Jaiswal, A. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.175802 · Cited by 41
RetractedTargeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277
Protein tyrosine phosphatases: from genes, to function, to disease
Tonks, N. K. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2039 · Cited by 1,677
Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer
Siegel, P. M., & Massagué, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1208 · Cited by 1,604
Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution
Taguchi, K., Motohashi, H., & Yamamoto, M. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01473.x · Cited by 1,478
Cited by
ROS function in redox signaling and oxidative stress
Schieber, M., & Chandel, N. S. (2014) · Current Biology · doi:10.1016/j.cub.2014.03.034 · Cited by 6,931
“By contrast, high levels of ROS generation due to loss of NRF2 lead to elevated levels of pro-inflammatory cytokines [101].”
BackgroundInfluentialThe emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579
Sies, H., Berndt, C., & Jones, D. P. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045037 · Cited by 3,520
Targeting oxidative stress in disease: Promise and limitations of antioxidant therapy
Forman, H. J., & Zhang, H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00233-1 · Cited by 2,900
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Wang, E., Sun, H., Wang, J., Wang, Z., Liu, H., Zhang, J. Z. H., & Hou, T. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00055 · Cited by 2,232
Sun, X., Ou, Z., Chen, R., Niu, X., Chen, D., Kang, R., & Tang, D. (2016) · Hepatology · doi:10.1002/hep.28251 · Cited by 2,012
“type and stage of the cancer.(7,8) For example, NRF2 prevents the initiation but accelerates the progression of chemical carcinogen-mediated or oncogene-mediated carcinogenesis.”
BackgroundThe KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis
Yamamoto, M., Kensler, T. W., & Motohashi, H. (2018) · Physiological Reviews · doi:10.1152/physrev.00023.2017 · Cited by 1,968
The Immunomodulatory and Anti-Inflammatory Role of Polyphenols
Yahfoufi, N., Alsadi, N., Jambi, M., & Matar, C. (2018) · Nutrients · doi:10.3390/nu10111618 · Cited by 1,737
“In vivo, curcumin can stimulate antioxidant enzymes like superoxide dismutase (SOD), catalase, and glutathione (GSH) peroxidase (Px) which lead to ROS detoxification [144].”
BackgroundThe Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer
Kansanen, E., Kuosmanen, S. M., Leinonen, H., & Levonen, A.-L. (2013) · Redox Biology · doi:10.1016/j.redox.2012.10.001 · Cited by 1,313
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
The Cancer Genome Atlas Research Network (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505917 · Cited by 1,336
Genetic landscape and biomarkers of hepatocellular carcinoma
Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325
Phosphorylation of p62 Activates the Keap1-Nrf2 Pathway during Selective Autophagy
Ichimura, Y., Waguri, S., Sou, Y.-S., Kageyama, S., Hasegawa, J., Ishimura, R., Saito, T., Yang, Y., Kouno, T., Fukutomi, T., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.08.003 · Cited by 1,205
“, 2011), the cells may possess somatic mutation(s) of Nrf2 and/or Keap1, similar to the cases of certain cancer cell lines (Kensler et al., 2007; Sporn and Liby, 2012).”
BackgroundResultInfluentialMechanisms of HBV-induced hepatocellular carcinoma
Levrero, M., & Zucman-Rossi, J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.021 · Cited by 1,052
Reactive Oxygen Species in Cancer: Current Findings and Future Directions
Nakamura, H., & Takada, K. (2021) · Cancer Science · doi:10.1111/cas.15068 · Cited by 1,027
Vaupel, P., Schmidberger, H., & Mayer, A. (2019) · International Journal of Radiation Biology · doi:10.1080/09553002.2019.1589653 · Cited by 893
“Aerobic glycolysis can minimize the production of ROS (Lu et al. 2015) which, at lower concentrations, can promote increased survival of cancer cells (Sporn and Liby 2012) as long as an adequate glucose supply is maintained (‘tumors act as glucose traps’, Shapot 1980).”
BackgroundThe Keap1–Nrf2–ARE Pathway As a Potential Preventive and Therapeutic Target: An Update
Lu, M., Ji, J., Jiang, Z., & You, Q. (2016) · Medicinal Research Reviews · doi:10.1002/med.21396 · Cited by 790
Mitochondrial reactive oxygen species and cancer
Sullivan, L. B., & Chandel, N. S. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-17 · Cited by 786
“This suppression was shown to be mediated by induction of the NRF2 antioxidant program, and thus it is not clear if oncogenes in this context modify the ROS production or simply decrease steady state ROS by increased expression of antioxidant proteins.”
BackgroundInfluentialMaj, T., Wang, W., Crespo, J., Zhang, H., Wang, W., Wei, S., Zhao, L., Vatan, L., Shao, I., Szeliga, W., et al. (2017) · Nature Immunology · doi:10.1038/ni.3868 · Cited by 733
Genetic landscape of esophageal squamous cell carcinoma
Gao, Y.-B., Chen, Z.-L., Li, J.-G., Hu, X.-D., Shi, X.-J., Sun, Z.-M., Zhang, F., Zhao, Z.-R., Li, Z.-T., Liu, Z.-Y., et al. (2014) · Nature Genetics · doi:10.1038/ng.3076 · Cited by 694
Toward clinical application of the Keap1-Nrf2 pathway
Suzuki, T., Motohashi, H., & Yamamoto, M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.005 · Cited by 680
Roh, J.-L., Kim, E. H., Jang, H., & Shin, D. (2017) · Redox Biology · doi:10.1016/j.redox.2016.12.010 · Cited by 662
Ferroptosis in cancer and cancer immunotherapy
Zhao, L., Zhou, X., Xie, F., Zhang, L., Yan, H., Huang, J., Zhang, C., Zhou, F., Chen, J., & Zhang, L. (2022) · Cancer Communications · doi:10.1002/cac2.12250 · Cited by 684
“NFE2-related factor 2 (NRF2) is a transcription factor that integrates cell stress signals and directs various transcription elements [127].”
BackgroundThe Dual Roles of NRF2 in Cancer
Menegon, S., Columbano, A., & Giordano, S. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.05.002 · Cited by 633
Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma
Hassannia, B., Wiernicki, B., Ingold, I., Qu, F., Van Herck, S., Tyurina, Y. Y., Bayır, H., Abhari, B. A., Angeli, J. P. F., Choi, S. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99032 · Cited by 627
Cell death and diseases related to oxidative stress: 4-hydroxynonenal (HNE) in the balance
Dalleau, S., Baradat, M., Guéraud, F., & Huc, L. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2013.138 · Cited by 580
“At low concentrations (less than 5mM), HNE has been reported to promote proliferation,(155) and a silent stimulation of antioxidant responses by low levels of HNE (hormesis) can be protective(72) against more drastic assaults such as by carcinogens.(142) At higher concentrations (20–100 mM), HNE causes cell cycle arre…”
BackgroundNrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer
Shin, D., Kim, E. H., Lee, J., & Roh, J.-L. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.10.426 · Cited by 534
Formation and Biological Targets of Quinones: Cytotoxic versus Cytoprotective Effects
Bolton, J. L., & Dunlap, T. (2017) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00256 · Cited by 522
An overview on the role of dietary phenolics for the treatment of cancers
Anantharaju, P. G., Gowda, P. C., Vimalambike, M. G., & Madhunapantula, S. V. (2016) · Nutrition Journal · doi:10.1186/s12937-016-0217-2 · Cited by 517
“For example, Nrf-2, a key redox regulator, is activated by gallic acid and causes the induction of chemoresistance [131].”
BackgroundNrf2/Keap1/ARE signaling: Towards specific regulation
Ulasov, A. V., Rosenkranz, A. A., Georgiev, G. P., & Sobolev, A. S. (2022) · Life Sciences · doi:10.1016/j.lfs.2021.120111 · Cited by 508
Autophagy in the liver: functions in health and disease
Ueno, T., & Komatsu, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.185 · Cited by 500
Rada, P., Rojo, A. I., Evrard-Todeschi, N., Innamorato, N. G., Cotte, A., Jaworski, T., Tobón-Velasco, J. C., Devijver, H., García-Mayoral, M. F., Van Leuven, F., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00180-12 · Cited by 474
The complexity of the Nrf2 pathway: beyond the antioxidant response
Huang, Y., Li, W., Su, Z.-Y., & Kong, A.-N. T. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.08.001 · Cited by 445
“[151,236,237]).”
Metabolic Regulation by p53 Family Members
Berkers, C. R., Maddocks, O. D. K., Cheung, E. C., Mor, I., & Vousden, K. H. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.06.019 · Cited by 446
Zhao, Y., Hu, Q., Cheng, F., Su, N., Wang, A., Zou, Y., Hu, H., Chen, X., Zhou, H.-M., Huang, X., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.04.009 · Cited by 433
Paradoxical Roles of Antioxidant Enzymes: Basic Mechanisms and Health Implications
Lei, X. G., Zhu, J.-H., Cheng, W.-H., Bao, Y., Ho, Y.-S., Reddi, A. R., Holmgren, A., & Arnér, E. S. J. (2016) · Physiological Reviews · doi:10.1152/physrev.00010.2014 · Cited by 429
Altered metabolite levels in cancer: implications for tumour biology and cancer therapy
Sullivan, L. B., Gui, D. Y., & Heiden, M. G. V. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.85 · Cited by 406
Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer
Koundouros, N., & Poulogiannis, G. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00160 · Cited by 415
“One of the most important implications of PI3K-mediated upregulation of Nrf2 signaling is promoting cancer cell survival by conferring protection against excessive oxidative stress (71, 72).”
BackgroundRedox homeostasis: The Golden Mean of healthy living
Ursini, F., Maiorino, M., & Forman, H. J. (2016) · Redox Biology · doi:10.1016/j.redox.2016.01.010 · Cited by 415
Mechanistic links between COPD and lung cancer
Houghton, A. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3477 · Cited by 414
Liby, K. T., & Sporn, M. B. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004846 · Cited by 405
“The emerging importance of Nrf2 and cancer is obviously relevant to SOs biology and has been reviewed extensively (Sporn and Liby, 2012).”
BackgroundSelf-citationNRF2-regulation in brain health and disease: Implication of cerebral inflammation
Sandberg, M., Patil, J., D'Angelo, B., Weber, S. G., & Mallard, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.11.004 · Cited by 390
“A similar type of argument concerning context biology of NRF2 in cancer was recently discussed (Sporn and Liby, 2012).”
Autophagy in liver diseases: A review
Qian, H., Chao, X., Williams, J., Fulte, S., Li, T., Yang, L., & Ding, W.-X. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.100973 · Cited by 373
Saito, T., Ichimura, Y., Taguchi, K., Suzuki, T., Mizushima, T., Takagi, K., Hirose, Y., Nagahashi, M., Iso, T., Fukutomi, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12030 · Cited by 362
Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma
Chen, F., Zhang, Y., Şenbabaoğlu, Y., Ciriello, G., Yang, L., Reznik, E., Shuch, B., Micevic, G., De Velasco, G., Shinbrot, E., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.024 · Cited by 359
“…a potentially novel RCC subtype (the “mixed” subtype) with patterns distinct from those of the three major RCC types (as well as those of oncocytoma (Tan et al., 2010)); (4) DNA copy unstable patterns and CDKN2A loss being associated with more aggressive clear cell as well as papillary RCC; (5)…”
BackgroundOxidative Stress, Inflammation, and Disease
Chatterjee, S. (2016) · Oxidative Stress and Biomaterials · doi:10.1016/b978-0-12-803269-5.00002-4 · Cited by 314
Natural product-derived pharmacological modulators of Nrf2/ARE pathway for chronic diseases
Kumar, H., Kim, I.-S., More, S. V., Kim, B.-W., & Choi, D.-K. (2014) · Nat. Prod. Rep. · doi:10.1039/c3np70065h · Cited by 333
Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population
Sawada, G., Niida, A., Uchi, R., Hirata, H., Shimamura, T., Suzuki, Y., Shiraishi, Y., Chiba, K., Imoto, S., Takahashi, Y., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.035 · Cited by 332
The role of reactive oxygen species and metabolism on cancer cells and their microenvironment
Costa, A., Scholer-Dahirel, A., & Mechta-Grigoriou, F. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.12.007 · Cited by 324
“[30] Sporn MB, Liby KT.”
The KEAP1-NRF2 pathway: Targets for therapy and role in cancer
Adinolfi, S., Patinen, T., Jawahar Deen, A., Pitkänen, S., Härkönen, J., Kansanen, E., Küblbeck, J., & Levonen, A.-L. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102726 · Cited by 292
The Role of Nrf2 Activity in Cancer Development and Progression
Zimta, A.-A., Cenariu, D., Irimie, A., Magdo, L., Nabavi, S. M., Atanasov, A. G., & Berindan-Neagoe, I. (2019) · Cancers · doi:10.3390/cancers11111755 · Cited by 292
“Nrf2 protects both normal and cancerous cells from oxidative damage, meaning that it inhibits malignant transformation; however, once cancer is installed, it offers resistance to therapy [28] (Figure 1).”
BackgroundRedox homeostasis: the linchpin in stem cell self-renewal and differentiation
Wang, K., Zhang, T., Dong, Q., Nice, E. C., Huang, C., & Wei, Y. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.50 · Cited by 288
“Nrf2 activates antioxidant responsive element (ARE)-dependent gene expression to maintain cellular redox homeostasis.(39) Nrf2 is sequestered in the cytoplasm by binding to Figure 2 Key regulators upstream of ROS in the self-renewal of stem cells.”
BackgroundPaul, M. K., Bisht, B., Darmawan, D. O., Chiou, R., Ha, V. L., Wallace, W. D., Chon, A. T., Hegab, A. E., Grogan, T., Elashoff, D. A., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.05.009 · Cited by 286
“Nrf2 and its repressor protein Keap1 are reported to act as major regulators of cellular redox levels (Sporn and Liby, 2012), and we therefore hypothesized that an increase in ROS flux can modulate Nrf2 activity.”
BackgroundHeme Oxygenase-1 Signaling and Redox Homeostasis in Physiopathological Conditions
Consoli, V., Sorrenti, V., Grosso, S., & Vanella, L. (2021) · Biomolecules · doi:10.3390/biom11040589 · Cited by 284
KEAP1 and done? Targeting the NRF2 pathway with sulforaphane
Dinkova-Kostova, A. T., Fahey, J. W., Kostov, R. V., & Kensler, T. W. (2017) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2017.02.002 · Cited by 273
“As thoughtfully addressed by Sporn and Liby (Sporn & Liby, 2012), the answers lie within the context of the speci fi c opportunities.”
BackgroundWoo, S. Y., Kim, J. H., Moon, M. K., Han, S.-H., Yeon, S. K., Choi, J. W., Jang, B. K., Song, H. J., Kang, Y. G., Kim, J. W., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401788m · Cited by 263
Role of Nrf2 and Its Activators in Respiratory Diseases
Liu, Q., Gao, Y., & Ci, X. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/7090534 · Cited by 267
“However, the effects of Nrf2 on cancer pathogenesis are still controversial in the lungs [161].”
BackgroundStructural and functional characterization of Nrf2 degradation by glycogen synthase kinase 3/β-TrCP
Cuadrado, A. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.04.029 · Cited by 260
Jiang, Z.-Y., Lu, M.-C., Xu, L., Yang, T.-T., Xi, M.-Y., Xu, X.-L., Guo, X.-K., Zhang, X.-J., You, Q.-D., & Sun, H.-P. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5000529 · Cited by 252
Epigenetic regulation of Keap1-Nrf2 signaling
Guo, Y., Yu, S., Zhang, C., & Kong, A.-N. T. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.013 · Cited by 258
“Furthermore, activation of Nrf2 confers neoplastic cells with growth and survival advantages during their transformation and progression [5].”
BackgroundIron and thiol redox signaling in cancer: an exquisite balance to escape ferroptosis
Toyokuni, S., Ito, F., Yamashita, K., Okazaki, Y., & Akatsuka, S. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.04.024 · Cited by 252
Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer
Bar-Peled, L., Kemper, E. K., Suciu, R. M., Vinogradova, E. V., Backus, K. M., Horning, B. D., Paul, T. A., Ichu, T.-A., Svensson, R. U., Olucha, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.051 · Cited by 262
“Many cancers counter a rise in oxidative stress by activating the NRF2 pathway, a master regulator of the cellular antioxidant response (Gorrini et al., 2013; Leinonen et al., 2014; Sporn and Liby, 2012).”
Biswas, C., Shah, N., Muthu, M., La, P., Fernando, A. P., Sengupta, S., Yang, G., & Dennery, P. A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.567685 · Cited by 256
Lin, D.-C., Wang, M.-R., & Koeffler, H. P. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.06.066 · Cited by 251
Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer
Lien, E. C., Lyssiotis, C. A., Juvekar, A., Hu, H., Asara, J. M., Cantley, L. C., & Toker, A. (2016) · Nature Cell Biology · doi:10.1038/ncb3341 · Cited by 249
Chang, J., Tan, W., Ling, Z., Xi, R., Shao, M., Chen, M., Luo, Y., Zhao, Y., Liu, Y., Huang, X., et al. (2017) · Nature Communications · doi:10.1038/ncomms15290 · Cited by 248
The Science behind Microgreens as an Exciting New Food for the 21st Century
Choe, U., Yu, L. L., & Wang, T. T. Y. (2018) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.8b03096 · Cited by 247
Targeting Neddylation Pathways to Inactivate Cullin-RING Ligases for Anticancer Therapy
Zhao, Y., Morgan, M. A., & Sun, Y. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5795 · Cited by 238
“The presence of drug was demonstrated by detecting (i) MLN4924-NEDD8 adducts in the BMAs of all 21 patients receiving the drug (www.eventureonline.com/eventure/publicAbstractView.do?id = 193668&congressId = 5650) and in 100% of the postdose tumor biopsies (http://mct.aacrjournals .org/cgi/content/meeting_abstract/10/1…”
BackgroundInfluentialHeme oxygenase-1: emerging target of cancer therapy
Chau, L.-Y. (2015) · Journal of Biomedical Science · doi:10.1186/s12929-015-0128-0 · Cited by 237
“Mutations in Nrf2 and its inhibitor, KEAP1, have recently been identified in human cancers [68].”
BackgroundParacrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine
Briggs, K. J., Koivunen, P., Cao, S., Backus, K. M., Olenchock, B. A., Patel, H., Zhang, Q., Signoretti, S., Gerfen, G. J., Richardson, A. L., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.042 · Cited by 235
Nrf2-p62 autophagy pathway and its response to oxidative stress in hepatocellular carcinoma
Bartolini, D., Dallaglio, K., Torquato, P., Piroddi, M., & Galli, F. (2018) · Translational Research · doi:10.1016/j.trsl.2017.11.007 · Cited by 235
Hourihan, J. M., Kenna, J. G., & Hayes, J. D. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4944 · Cited by 233
“Although xenobiotic-inducing agents are commonly used as a means to activate Nrf2 via modification of Keap1 thiols (41, 62, 64), the ability of endogenous signaling molecules to inhibit Keap1 has attracted little attention.”
Mehine, M., Kaasinen, E., Heinonen, H.-R., Mäkinen, N., Kämpjärvi, K., Sarvilinna, N., Aavikko, M., Vähärautio, A., Pasanen, A., Bützow, R., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518752113 · Cited by 229
“Activation of NRF2 has recently been identified as a common feature of many cancers (52).”
BackgroundMarchev, A. S., Dimitrova, P. A., Burns, A. J., Kostov, R. V., Dinkova‐Kostova, A. T., & Georgiev, M. I. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13407 · Cited by 222
FOXO transcription factors as mediators of stress adaptation
Rodriguez-Colman, M. J., Dansen, T. B., & Burgering, B. M. T. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00649-0 · Cited by 218
“181).”
Li, X., Duan, L., Yuan, S., Zhuang, X., Qiao, T., & He, J. (2019) · Journal of Inflammation · doi:10.1186/s12950-019-0216-0 · Cited by 218
Targeting the JAK/STAT Signaling Pathway Using Phytocompounds for Cancer Prevention and Therapy
Bose, S., Banerjee, S., Mondal, A., Chakraborty, U., Pumarol, J., Croley, C. R., & Bishayee, A. (2020) · Cells · doi:10.3390/cells9061451 · Cited by 214
“The idea of chemoprevention is receiving extensive awareness because it is a cost-effective option for cancer control when compared to conventional chemotherapy [6,7].”
BackgroundMechanistic targeting of advanced glycation end-products in age-related diseases
Rowan, S., Bejarano, E., & Taylor, A. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.08.036 · Cited by 215
Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1
Na, H.-K., & Surh, Y.-J. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.10.819 · Cited by 202
“Inhibition of Nrf2 overexpression has been known to reverse the phenotypic characteristics of cancer cells, lending support to this supposition [7].”
ResultOncogenic functions of the transcription factor Nrf2
Gañán-Gómez, I., Wei, Y., Yang, H., Boyano-Adánez, M. C., & García-Manero, G. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.06.041 · Cited by 202
“Thus, the beneficial effects of the activation of Nrf2 signaling in cancer have become a controversial issue (reviewed in [38]).”
BackgroundOxidative Stress in Autism Spectrum Disorder—Current Progress of Mechanisms and Biomarkers
Liu, X., Lin, J., Zhang, H., Khan, N. U., Zhang, J., Tang, X., Cao, X., & Shen, L. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.813304 · Cited by 201
Lian, G., Gnanaprakasam, J. R., Wang, T., Wu, R., Chen, X., Liu, L., Shen, Y., Yang, M., Yang, J., Chen, Y., et al. (2018) · eLife · doi:10.7554/elife.36158 · Cited by 196
Xu, G., Li, C., Chi, C., Wu, L., Sun, Y., Zhao, J., Xia, X.-H., & Gou, S. (2022) · Nature Communications · doi:10.1038/s41467-022-30721-w · Cited by 189
Ge, W., Zhao, K., Wang, X., Li, H., Yu, M., He, M., Xue, X., Zhu, Y., Zhang, C., Cheng, Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.008 · Cited by 188
“…in cancer, it is no surprise that constitutive activation of Nrf2 has frequently been detected in human cancers and also related to resistance to chemotherapies in established cancers (DeNicola et al., 2011; Inami et al., 2011; Jiang et al., 2010; Sporn and Liby, 2012; Wang et al., 2008).”
BackgroundNrf2-A regulator of keratinocyte redox signaling
Schäfer, M., & Werner, S. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.04.018 · Cited by 192
“This topic has been extensively studied for various types of cancer [53, 54],”
BackgroundEmerging Regulatory Paradigms in Glutathione Metabolism
(2014) · Advances in Cancer Research · doi:10.1016/b978-0-12-420117-0.00002-5 · Cited by 186
The transcription factor NF‐E2‐related Factor 2 (Nrf2): a protooncogene?
Shelton, P., & Jaiswal, A. K. (2013) · The FASEB Journal · doi:10.1096/fj.12-217257 · Cited by 186
“role is dependent on the stage of tumorigenesis (66).”
BackgroundInfluentialPrinciples and functions of metabolic compartmentalization
Bar-Peled, L., & Kory, N. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00645-2 · Cited by 181
Coffee consumption and disease correlations
Gökcen, B. B., & Şanlier, N. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2017.1369391 · Cited by 184
“transcription factor, (Sporn and Liby, 2012) and Nrf2 activation”
Potential Applications of NRF2 Inhibitors in Cancer Therapy
Panieri, E., & Saso, L. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8592348 · Cited by 184
Drug Resistance in Glioblastoma: The Two Faces of Oxidative Stress
Olivier, C., Oliver, L., Lalier, L., & Vallette, F. M. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.620677 · Cited by 182
“The translocation of Nrf-2 to the nucleus caused by OS has been shown to activate the glutamate cysteine ligase modifier subunit, glutathione S-transferase π, GSH availability and use, glutathione reductase, and glutathione peroxidase (Sporn and Liby, 2012; Rocha et al., 2016).”
BackgroundLu, K., Alcivar, A. L., Ma, J., Foo, T. K., Zywea, S., Mahdi, A., Huo, Y., Kensler, T. W., Gatza, M. L., & Xia, B. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2204 · Cited by 181
Luo, J.-F., Shen, X.-Y., Lio, C. K., Dai, Y., Cheng, C.-S., Liu, J.-X., Yao, Y.-D., Yu, Y., Xie, Y., Luo, P., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00911 · Cited by 180
“, 2009), neurodegenerative diseases (Joshi and Johnson, 2012), cancer (Sporn and Liby, 2012), type 2 diabetes (Chartoumpekis and Kensler, 2013), chronic kidney disease (Ruiz et al.”
BackgroundHoughton, C. A. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/2716870 · Cited by 179
“An important new concern they suggest is the finding that common oncogenes, such as KRAS, BRAF, and MYC, all increase the transcription and activity of NRF2, resulting in an increase in cytoprotective activity within the cancer cell [115].”
BackgroundGruosso, T., Mieulet, V., Cardon, M., Bourachot, B., Kieffer, Y., Devun, F., Dubois, T., Dutreix, M., Vincent‐Salomon, A., Miller, K. M., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505891 · Cited by 179
“Interestingly, the same downregulation of total H2AX protein levels was also detected in Nrf2-deficient (Nfe2l2 / ) fibroblasts (Fig 1A, right), another well-known model of chronic oxidative stress (Sporn & Liby, 2012).”
BackgroundDiscovery and development of natural product oridonin-inspired anticancer agents
Ding, Y., Ding, C., Ye, N., Liu, Z., Wold, E. A., Chen, H., Wild, C., Shen, Q., & Zhou, J. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.06.015 · Cited by 178
Cancer drug resistance: redox resetting renders a way
Liu, Y., Li, Q., Zhou, L., Xie, N., Nice, E. C., Zhang, H., Huang, C., & Lei, Y. (2106) · Oncotarget · doi:10.18632/oncotarget.8600 · Cited by 177
“Recent studies showed that higher levels of NRF2 could promote tumorigenesis and contribute to chemoresistance, suggesting a “dark side” of the NRF2 pathway [38-43].”
BackgroundBradford, P. G. (2013) · BioFactors · doi:10.1002/biof.1074 · Cited by 175
“Nrf2 has been extensively studied for its protective role in suppressing oxidative stress and inhibiting carcinogenesis [87].”
BackgroundKeap Calm, and Carry on Covalently
Wilson, A. J., Kerns, J. K., Callahan, J. F., & Moody, C. J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400224q · Cited by 171
Metadata
- Authors
- Sporn, M. B., & Liby, K. T.
- Affiliations
- Dartmouth College (US)
- Corresponding author
- Sporn, Michael B.
- Liby, Karen T.
- ORCID
- Liby, Karen T.
- Venue
- Nature Reviews Cancer
- Published
- 2012-07-19
- Volume
- 12
- Issue
- 8
- Pages
- 564-571
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3836441
- OpenAlex
- W2030749349
- Cited by
- 1,067
- References
- 120
- Citations by year
- 2026: 36 · 2025: 48 · 2024: 70 · 2023: 72 · 2022: 88 · 2021: 90 · 2020: 97 · 2019: 93 · 2018: 112 · 2017: 88 · 2016: 93 · 2015: 62 · 2014: 57 · 2013: 50 · 2012: 11
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA078814, P30CA023108)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glutathione Transferases and Polymorphisms
- Keywords
- Nrf2, chemoprevention, carcinogenesis, chemoresistance, transcription factor activation
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Neoplasms, Anticarcinogenic Agents, Tumor Suppressor Proteins, NF-E2-Related Factor 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.